Pharma company Gufic buys Lodha Avalon duplex in Juhu for ₹236 crore
Macrotech is in focus.
· LiveMint Companies
The purchase adds to a growing list of high-value deals at Lodha Developers’ luxury Mumbai project, which has attracted pharmaceutical promoters and business executives.
The analysis
Macrotech reported ₹236 crore. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -0.8% on the day at ₹1,037.00, and has returned -19.4% over three months. It sits 21% below its 52-week high. The real estate sector has moved -13.7% over the same period, so Macrotech is running 5.7 points behind its peers.
For Macrotech, the question is how much of this is already reflected in the price and how much re-rates the real estate peer set alongside it.
Market context
- In focus: Macrotech (Lodha) (LODHA), in Real Estate.
- Over three months: Macrotech (Lodha) -19.4% against Real Estate -13.7% (5.7 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Macrotech (Lodha)LODHA · Real Estate | ₹1,037.00 | -0.8% | -8.6% | -19.4% | -21.2% | 0.9× | — |
Real Estate
1M -7.4% · 3M -13.7%
Macrotech (Lodha)
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Lodha Developers makes NCR market debut with ₹1,700 crore office project
Lodha Developers Q2 PAT rises 28%, expects to exceed FY27 profit guidance
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Regulator orders Sun Pharma to shut Assam plant over eye-drop quality lapses; what you should know
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings